Deprenyl, an old drug with new anticancer potential: Mini review

TL;DR

This mini review highlights the potential of L-Deprenyl as an anticancer agent, demonstrating its ability to induce apoptosis, enhance immune response, and improve the efficacy of chemotherapy with low toxicity.

Contribution

It summarizes existing preclinical and clinical evidence supporting L-Deprenyl's anticancer effects and its potential repurposing for cancer therapy.

Findings

L-Deprenyl induces apoptosis in various cancer cell lines.

DEP enhances immune activity and synergizes with chemotherapy drugs.

DEP shows low toxicity and potential benefits in cancer and Parkinson's disease.

Abstract

The anticancer potential of monoamine oxidase (MAO) was observed in pre-clinical assays conducted with cell cultures and animals. L-Deprenyl (DEP) causes apoptosis in melanoma, leukemia and mammary cells. High-dose DEP has shown toxicity in mammary and pituitary cancers, as well as in monoblastic leukemia, in rats. DEP accounts for immune-stimulant effect capable of increasing natural killer cell activity, IL-2 generation, as well as of inhibiting tumor growth. DEP administration in old female rats has increased IL-2 generation and inverted the age-related depletion of IFN-{\gamma} generation in the spleen. Co-adjuvant DEP administration helped preventing/mitigating symptoms associated with peripheral neuropathy in cancer treatment. It also enhanced the cytotoxic effects of antineoplastic drugs - such as doxorubicin, cisplatin, among others - in cancer cells while they protected healthy cells from being damaged. DEP presented effect against dysfunctions such as debilitating hormone imbalance triggered by pituitary gland tumor; this gland produces the stimulatory hormone of adrenocorticotropic hormone which was related to the exacerbation of this disease. Thus, DEP emerges as an excellent potential drug against several cancer types and it also presents low toxicity in Parkinson`s disease patients subjected to long treatment with it.